Cantor Fitzgerald Increases Earnings Estimates for Alector

Alector, Inc. (NASDAQ:ALEC) – Equities research analysts at Cantor Fitzgerald lifted their FY2025 EPS estimates for shares of Alector in a research report issued to clients and investors on Monday, November 10th. Cantor Fitzgerald analyst P. Stavropoulos now forecasts that the company will post earnings per share of ($1.50) for the year, up from their prior estimate of ($1.63). Cantor Fitzgerald has a “Neutral” rating on the stock. The consensus estimate for Alector’s current full-year earnings is ($1.88) per share. Cantor Fitzgerald also issued estimates for Alector’s FY2026 earnings at ($0.73) EPS.

Alector (NASDAQ:ALEC) last released its quarterly earnings data on Thursday, November 6th. The company reported ($0.34) EPS for the quarter, beating the consensus estimate of ($0.42) by $0.08. The business had revenue of $3.26 million for the quarter, compared to the consensus estimate of $3.49 million. Alector had a negative net margin of 156.03% and a negative return on equity of 123.02%. Alector has set its FY 2025 guidance at EPS.

Several other equities research analysts also recently weighed in on the company. Cowen downgraded Alector to a “hold” rating in a research report on Wednesday, October 22nd. Wall Street Zen lowered Alector from a “hold” rating to a “sell” rating in a report on Friday, September 26th. William Blair cut Alector from an “outperform” rating to a “market perform” rating in a research report on Wednesday, October 22nd. Weiss Ratings restated a “sell (d-)” rating on shares of Alector in a research report on Wednesday, October 8th. Finally, TD Cowen cut shares of Alector from a “buy” rating to a “hold” rating in a research note on Wednesday, October 22nd. One investment analyst has rated the stock with a Buy rating, seven have issued a Hold rating and three have issued a Sell rating to the stock. Based on data from MarketBeat.com, Alector presently has a consensus rating of “Reduce” and a consensus target price of $3.00.

Alector Trading Down 10.4%

Shares of Alector stock opened at $1.20 on Wednesday. The stock has a market cap of $130.98 million, a PE ratio of -1.12 and a beta of 0.93. The firm has a fifty day moving average price of $2.49 and a 200 day moving average price of $1.93. Alector has a 1 year low of $0.87 and a 1 year high of $5.16. The company has a debt-to-equity ratio of 0.17, a current ratio of 3.76 and a quick ratio of 3.76.

Insider Buying and Selling

In other news, Director Paula Hammond sold 14,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 26th. The stock was sold at an average price of $2.36, for a total value of $33,040.00. Following the completion of the sale, the director directly owned 74,909 shares in the company, valued at $176,785.24. The trade was a 15.75% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders own 9.70% of the company’s stock.

Institutional Investors Weigh In On Alector

A number of institutional investors have recently added to or reduced their stakes in the stock. Acadian Asset Management LLC lifted its holdings in Alector by 39.8% during the first quarter. Acadian Asset Management LLC now owns 1,440,661 shares of the company’s stock valued at $1,768,000 after purchasing an additional 410,205 shares in the last quarter. Ieq Capital LLC purchased a new stake in shares of Alector during the first quarter worth about $99,000. Jacobs Levy Equity Management Inc. raised its position in shares of Alector by 25.9% during the 1st quarter. Jacobs Levy Equity Management Inc. now owns 1,334,032 shares of the company’s stock worth $1,641,000 after purchasing an additional 274,341 shares during the last quarter. Invesco Ltd. lifted its stake in Alector by 209.6% in the 1st quarter. Invesco Ltd. now owns 148,576 shares of the company’s stock valued at $183,000 after buying an additional 100,591 shares in the last quarter. Finally, Vanguard Personalized Indexing Management LLC lifted its stake in Alector by 49.2% in the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 52,095 shares of the company’s stock valued at $73,000 after buying an additional 17,170 shares in the last quarter. Institutional investors and hedge funds own 85.83% of the company’s stock.

About Alector

Alector, Inc, a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases.